The 'Sell' rating maintained by UBS indicates a negative outlook for DocuSign. However, the increase in price target from $44 to $48 suggests that the analyst sees some potential for the stock's price to rise in the short term, despite the overall negative rating. This could lead to mixed reactions in the market, potentially causing volatility in the stock's price.